Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The variable clinical outcome of patients with G2 & G3 well diff GEP-NETs makes the selection
of an optimal treatment strategy challenging.
Initial data suggests that high DOTATATE uptake and low FDG uptake are suggestive of low
grade disease, with an indolent course.
Conversely, low DT uptake and high FDG uptake are suggestive of high-grade/ aggressive
disease.
G2/3 GEP NETs may be biologically diverse; clinically relevant cohort for dual-tracer PET
imaging.
Our secondary objectives are
1. To determine the distribution of PETNET scores derived from 18F-FDG & 68Ga-DT PET in
patients with G2 & G3 well diff GEP-NETs.
2. To determine the proportion of patients in whom the addition of 18F-FDG PET data results
in a change in planned clinical management.
To assess intra-individual variability in SSTR expression & glucose metabolism (as seen on DT
and FDG PET) across different tumor sites within the same patient.
2) To determine whether a correlation exists between tumor texture features on 68Ga-DT & FDG
PET to tumor grade and Ki 67 index.
3) To assess for an association between tumor texture features on 68Ga-DT PET and glucose
metabolism; and/or an association between tumor texture features on FDG PET and SSTR
expression.